Ranbaxy extends losses in Q3 but merger with Sun on track
This article was originally published in Scrip
Executive Summary
Ahead of its proposed combination with Sun Pharma, Ranbaxy Laboratories reported disappointing numbers for the third quarter ended December 2014, with net losses widening to INR10.29bn ($168m) dented by higher finance costs and foreign exchange losses.